Header

UZH-Logo

Maintenance Infos

Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease


Zerr, Pawel; Palumbo-Zerr, Katrin; Distler, Alfiya; Tomcik, Michal; Vollath, Stefan; Munoz, Luis E; Beyer, Christian; Dees, Clara; Egberts, Friederike; Tinazzi, Ilaria; Del Galdo, Francesco; Distler, Oliver; Schett, Georg; Spriewald, Bernd M; Distler, Jörg H W (2012). Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 120(14):2909-2917.

Abstract

Chronic graft-versus-host disease (cGVHD) is a prognosis limiting complication of allogeneic stem cell transplantation. The molecular mechanisms underlying cGVHD are incompletely understood, and targeted therapies are not yet established for clinical use. Here we examined the role of the hedgehog pathway in sclerodermatous cGVHD. Hedgehog signaling was activated in human and murine cGVHD with increased expression of sonic hedgehog and accumulation of the transcription factors Gli-1 and Gli-2. Treatment with LDE223, a highly selective small-molecule antagonist of the hedgehog coreceptor Smoothened (Smo), abrogated the activation of hedgehog signaling and protected against experimental cGVHD. Preventive therapy with LDE223 almost completely impeded the development of clinical and histologic features of sclerodermatous cGVHD. Treatment with LDE223 was also effective, when initiated after the onset of clinical manifestations of cGVHD. Hedgehog signaling stimulated the release of collagen from cultured fibroblasts but did not affect leukocyte influx in murine cGVHD, suggesting direct, leukocyte-independent stimulatory effects on fibroblasts as the pathomechanism of hedgehog signaling in cGVHD. Considering the high morbidity of cGVHD, the current lack of efficient molecular therapies for clinical use, and the availability of well-tolerated inhibitors of Smo, targeting hedgehog signaling might be a novel strategy for clinical trials in cGVHD.

Abstract

Chronic graft-versus-host disease (cGVHD) is a prognosis limiting complication of allogeneic stem cell transplantation. The molecular mechanisms underlying cGVHD are incompletely understood, and targeted therapies are not yet established for clinical use. Here we examined the role of the hedgehog pathway in sclerodermatous cGVHD. Hedgehog signaling was activated in human and murine cGVHD with increased expression of sonic hedgehog and accumulation of the transcription factors Gli-1 and Gli-2. Treatment with LDE223, a highly selective small-molecule antagonist of the hedgehog coreceptor Smoothened (Smo), abrogated the activation of hedgehog signaling and protected against experimental cGVHD. Preventive therapy with LDE223 almost completely impeded the development of clinical and histologic features of sclerodermatous cGVHD. Treatment with LDE223 was also effective, when initiated after the onset of clinical manifestations of cGVHD. Hedgehog signaling stimulated the release of collagen from cultured fibroblasts but did not affect leukocyte influx in murine cGVHD, suggesting direct, leukocyte-independent stimulatory effects on fibroblasts as the pathomechanism of hedgehog signaling in cGVHD. Considering the high morbidity of cGVHD, the current lack of efficient molecular therapies for clinical use, and the availability of well-tolerated inhibitors of Smo, targeting hedgehog signaling might be a novel strategy for clinical trials in cGVHD.

Statistics

Citations

21 citations in Web of Science®
23 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

243 downloads since deposited on 14 Feb 2013
47 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:14 Feb 2013 16:33
Last Modified:05 Apr 2016 16:27
Publisher:American Society of Hematology
ISSN:0006-4971
Additional Information:This research was originally published in Blood. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Copyright by the American Society of Hematology
Publisher DOI:https://doi.org/10.1182/blood-2012-01-403428
PubMed ID:22915638

Download

Download PDF  'Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease'.
Preview
Content: Published Version
Filetype: PDF
Size: 635kB
View at publisher